Antiangiogenic treatment for multiple CNS hemangioblastomas

Onkologie

Volumn 35, Issue 7-8, 2012, Pages 443-445

  Riklin, Christian ^a   Seystahl, Katharina ^b   Hofer, Silvia ^a   Happold, Caroline ^b   Winterhalder, Ralph ^a   Weller, Michael ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiangiogenesis; Bevacizumab; Hemangioblastoma; Von Hippel Lindau syndrome

Indexed keywords

BEVACIZUMAB; CARBAMAZEPINE; DEXAMETHASONE; SUNITINIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN STEM; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CEREBELLUM; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPILEPSY; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR GROWTH; TUMOR RECURRENCE; VON HIPPEL LINDAU DISEASE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; HEMANGIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84864614266     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000341075     Document Type: Article

References (12)

1. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B: Von hippel-lindau disease: Genetic, clinical, and imaging features. Radiology 1995;194:629-642.
2. Takai K, Taniguchi M, Takahashi H, Usui M, Saito N: Comparative analysis of spinal hemangioblastomas in sporadic disease and von Hippel- Lindau syndrome. Neurol Med Chir (Tokyo) 2010; 50:560-567.
3. Richard S, Beigelman C, Gerber S, Van Effenterre R, Gaudric A, Sahel M, Binaghi M, De Kersaint- Gilly A, Houtteville JP, Brunon JP, et al.: (Does hemangioblastoma exist outside von Hippel- Lindau disease?). Neurochirurgie 1994;40:145-154.
4. Asthagiri AR, Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, Lonser RR: Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro-Oncology 2010;12:80-86
5. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH: Von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
6. Krieg M, Marti HH, Plate KH: Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998;92:3388-3393.
7. Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau diseaseassociated and sporadic hemangioblastomas. Cancer Res 1995;55:1358-1364.
8. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, Kiss JZ, Dietrich PY, De Tribolet N, Pizzolato GP, Pepper MS: Expression and localization of VEGF-c and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 2006;209:34-43.
9. De Klerk T, Steel D: Use of intravitreal bevacizumab in a patient with a von Hippel-Lindau-associated retinal haemangioblastoma of the optic nerve head: A case eport. J Med Case Rep 2008;2: 182.
10. Hrisomalos FN, Maturi RK, Pata V: Long-term use of intravitreal bevacizumab (avastin) for the treatment of von Hippel-Lindau associated retinal hemangioblastomas. Open Ophthalmol J 2010;4: 66-69.
11. Steeghs N, Rabelink TJ, op 't Roodt J, Batman E, Cluitmans FHM, Weijl NI, de Koning E, Gelderblom H: Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 2010;21:1100-1105.
12. Keunen O, Johansson M, Oudin As, Sanzey M, Rahim SAA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP: Anti- VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-3754.